Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment

Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment ...
European Medical Journal

HARMONY Model Enhances Risk Assessment in AML

NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
The National Law Review

Moleculin Issues New Positive AML Overall Survival Data:

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L ...
The American Journal of Managed Care

Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...